A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Study of Drug Combination in Subjects with Triple Negative Breast Cancer or Colorectal Cancer with Liver Metastases
Sponsor: Amgen
Enrolling: Male and Female Patients
IRB Number: AAAR2673
U.S. Govt. ID: NCT03256344
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out whether the drug talimogene laherparepvec in combination with another drug atezolizumab is safe for people with triple negative breast cancer or colorectal cancer with liver metastases and whether this drug combination causes any side effects.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Are you 18 years or older? Yes No
Do you have triple negative breast cancer with liver metastases OR colorectal cancer with liver metastases? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE